IL162031A0 - Chemically-modified human growth hormone conjugates - Google Patents
Chemically-modified human growth hormone conjugatesInfo
- Publication number
- IL162031A0 IL162031A0 IL16203102A IL16203102A IL162031A0 IL 162031 A0 IL162031 A0 IL 162031A0 IL 16203102 A IL16203102 A IL 16203102A IL 16203102 A IL16203102 A IL 16203102A IL 162031 A0 IL162031 A0 IL 162031A0
- Authority
- IL
- Israel
- Prior art keywords
- chemically
- growth hormone
- human growth
- modified human
- hormone conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33190701P | 2001-11-20 | 2001-11-20 | |
| PCT/US2002/037270 WO2003044056A2 (en) | 2001-11-20 | 2002-11-20 | Chemically-modified human growth hormone conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162031A0 true IL162031A0 (en) | 2005-11-20 |
Family
ID=23295870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16203102A IL162031A0 (en) | 2001-11-20 | 2002-11-20 | Chemically-modified human growth hormone conjugates |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1453859A2 (en) |
| JP (2) | JP2005525302A (en) |
| KR (2) | KR20050044858A (en) |
| CN (1) | CN1608079A (en) |
| AP (1) | AP2004003050A0 (en) |
| AU (1) | AU2002356990A1 (en) |
| BR (1) | BR0214451A (en) |
| CA (1) | CA2467731A1 (en) |
| CO (1) | CO5580794A2 (en) |
| EA (2) | EA200700431A1 (en) |
| EC (1) | ECSP045114A (en) |
| GE (1) | GEP20063860B (en) |
| HR (1) | HRP20040448A2 (en) |
| HU (1) | HUP0500997A2 (en) |
| IL (1) | IL162031A0 (en) |
| IS (1) | IS7268A (en) |
| MA (1) | MA27544A1 (en) |
| MX (1) | MXPA04004809A (en) |
| NO (1) | NO20042182L (en) |
| OA (1) | OA13063A (en) |
| PL (1) | PL374354A1 (en) |
| RS (1) | RS53104A (en) |
| TN (1) | TNSN04090A1 (en) |
| WO (1) | WO2003044056A2 (en) |
| ZA (1) | ZA200403907B (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| US7041855B2 (en) | 2001-12-11 | 2006-05-09 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| US6956135B2 (en) | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| WO2003049699A2 (en) * | 2001-12-11 | 2003-06-19 | Sun Bio, Inc. | Novel monofunctional polyethylene glycol aldehydes |
| US6916962B2 (en) | 2001-12-11 | 2005-07-12 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| WO2003061577A2 (en) * | 2002-01-18 | 2003-07-31 | Biogen Idec Ma Inc. | Polyalkylene glycol with moiety for conjugating biologically active compound |
| EP1591467A1 (en) * | 2002-09-09 | 2005-11-02 | Nektar Therapeutics Al, Corporation | Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone |
| CA2498167C (en) | 2002-09-09 | 2012-03-20 | Nektar Therapeutics Al, Corporation | Water-soluble polymer alkanals |
| US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| US20050281778A1 (en) * | 2003-03-28 | 2005-12-22 | Myung-Ok Park | Human growth hormone conjugated with biocompatible polymer |
| EP1673464A2 (en) * | 2003-10-10 | 2006-06-28 | Novo Nordisk A/S | Conjugation of peptides |
| US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| BRPI0506864A (en) * | 2004-01-21 | 2007-05-29 | Novo Nordisk As | method for conjugating peptides, conjugated peptide, compound and pharmaceutically acceptable salts, prodrugs and solvates thereof, pharmaceutical composition, use of a compound, and method for treating disease |
| CN101010105A (en) * | 2004-08-31 | 2007-08-01 | 法玛西雅厄普约翰有限责任公司 | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
| WO2006073846A2 (en) * | 2004-12-22 | 2006-07-13 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone |
| SG158149A1 (en) | 2004-12-22 | 2010-01-29 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| BRPI0519430A2 (en) | 2004-12-22 | 2009-02-10 | Ambrx Inc | modified human growth hormone |
| US20090105134A1 (en) | 2005-02-10 | 2009-04-23 | Novo Nordisk A/S | C-Terminally Pegylated Growth Hormones |
| MX2007012887A (en) | 2005-04-18 | 2007-12-10 | Novo Nordisk As | Il-21 variants. |
| BRPI0615351A2 (en) * | 2005-08-30 | 2011-05-17 | Novo Nordisk Healthcare Ag | liquid formulations of pegylated growth hormone |
| CN104710503B (en) * | 2005-11-08 | 2023-04-25 | Ambrx 公司 | Promoters for modification of unnatural amino acids and unnatural amino acid polypeptides |
| CA2882445A1 (en) | 2005-12-14 | 2007-06-21 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| WO2008003750A2 (en) * | 2006-07-07 | 2008-01-10 | Novo Nordisk Health Care Ag | New protein conjugates and methods for their preparation |
| CN101108895B (en) * | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | Polyglycol ethanal derivant and combo of medicament and the same |
| WO2008049920A2 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | Il-21 variants |
| CL2008002399A1 (en) * | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c. |
| PL2272875T3 (en) * | 2008-04-03 | 2014-06-30 | Biosteed Gene Expression Tech Co Ltd | Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof |
| KR101104574B1 (en) * | 2008-05-14 | 2012-01-11 | 성균관대학교산학협력단 | Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same |
| BRPI0911722B1 (en) * | 2008-07-31 | 2022-09-13 | Pharmaessentia Corp | PEPTIDE-POLYMER CONJUGATE |
| BRPI0917000A2 (en) | 2008-08-06 | 2016-02-16 | Novo Nordisk Healthcare Ag | protein conjugates with prolonged in vivo efficacy |
| RU2409669C9 (en) * | 2008-08-18 | 2012-05-27 | ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") | Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods |
| WO2010030366A2 (en) * | 2008-09-11 | 2010-03-18 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
| MX2011007736A (en) | 2009-01-22 | 2011-09-06 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds. |
| CN105963710A (en) | 2009-08-06 | 2016-09-28 | 诺沃—诺迪斯克保健股份有限公司 | Growth hormones with prolonged in-vivo efficacy |
| SG181648A1 (en) | 2009-12-15 | 2012-07-30 | Ascendis Pharma As | Dry growth hormone composition transiently linked to a polymer carrier |
| JP5980689B2 (en) | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Stable growth hormone compound |
| PL2525834T3 (en) | 2010-01-22 | 2020-10-19 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
| WO2011146518A2 (en) * | 2010-05-17 | 2011-11-24 | Cebix Inc. | Pegylated c-peptide |
| EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
| EA019967B1 (en) * | 2011-12-21 | 2014-07-30 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Polyethyleneglycol covalent conjugate with human growth hormone |
| ES2841123T3 (en) | 2013-04-05 | 2021-07-07 | Formulacion Del Compuesto De La Hormona De Crecimiento | Growth hormone compound formulation |
| JP6820841B2 (en) | 2014-11-06 | 2021-01-27 | ファーマエッセンティア コーポレイション | Dosing regimen for pegged interferon |
| KR20170125839A (en) * | 2015-03-11 | 2017-11-15 | 넥타르 테라퓨틱스 | Conjugates of an il-7 moiety and an polymer |
| SG11201802180TA (en) * | 2015-09-18 | 2018-04-27 | Univ Miyazaki | Long-acting adrenomedullin derivative |
| CN114539384A (en) * | 2020-11-19 | 2022-05-27 | 江苏众红生物工程创药研究院有限公司 | Pegylated long-acting growth hormone, and preparation method and medical application thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| DE69128944T2 (en) * | 1990-05-04 | 1998-06-25 | American Cyanamid Co | Stabilization of somatotropin through modification of cysteine residues |
| WO1992016555A1 (en) * | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| WO1993000109A1 (en) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5849535A (en) * | 1995-09-21 | 1998-12-15 | Genentech, Inc. | Human growth hormone variants |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| WO1999003887A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| BR0008759B1 (en) * | 1999-01-14 | 2014-03-11 | Bolder Biotechnology Inc | Methods for the production of protein containing free cysteine residues |
| HU228488B1 (en) * | 1999-01-29 | 2013-03-28 | Amgen Inc | Gcsf conjugates |
| AU2001289307A1 (en) * | 2000-04-06 | 2001-10-23 | Pharmacia Corporation | Chemically-modified myelopoietin conjugates |
| EP1352062A2 (en) * | 2001-01-11 | 2003-10-15 | Maxygen Aps | Improved growth hormone molecules |
-
2002
- 2002-11-20 KR KR1020047007708A patent/KR20050044858A/en active IP Right Grant
- 2002-11-20 HU HU0500997A patent/HUP0500997A2/en unknown
- 2002-11-20 WO PCT/US2002/037270 patent/WO2003044056A2/en not_active Application Discontinuation
- 2002-11-20 EA EA200700431A patent/EA200700431A1/en unknown
- 2002-11-20 CA CA002467731A patent/CA2467731A1/en not_active Abandoned
- 2002-11-20 BR BRPI0214451-4A patent/BR0214451A/en not_active IP Right Cessation
- 2002-11-20 OA OA1200400143A patent/OA13063A/en unknown
- 2002-11-20 AU AU2002356990A patent/AU2002356990A1/en not_active Abandoned
- 2002-11-20 EP EP02803695A patent/EP1453859A2/en not_active Withdrawn
- 2002-11-20 EA EA200400565A patent/EA008505B1/en unknown
- 2002-11-20 GE GE5599A patent/GEP20063860B/en unknown
- 2002-11-20 JP JP2003545691A patent/JP2005525302A/en active Pending
- 2002-11-20 PL PL02374354A patent/PL374354A1/en unknown
- 2002-11-20 RS YU53104A patent/RS53104A/en unknown
- 2002-11-20 IL IL16203102A patent/IL162031A0/en unknown
- 2002-11-20 CN CNA028259289A patent/CN1608079A/en active Pending
- 2002-11-20 MX MXPA04004809A patent/MXPA04004809A/en not_active Application Discontinuation
- 2002-11-20 KR KR1020077011730A patent/KR20070072924A/en not_active Application Discontinuation
- 2002-11-20 AP APAP/P/2004/003050A patent/AP2004003050A0/en unknown
-
2004
- 2004-05-17 IS IS7268A patent/IS7268A/en unknown
- 2004-05-19 MA MA27686A patent/MA27544A1/en unknown
- 2004-05-20 EC EC2004005114A patent/ECSP045114A/en unknown
- 2004-05-20 HR HR20040448A patent/HRP20040448A2/en not_active Application Discontinuation
- 2004-05-20 TN TNP2004000090A patent/TNSN04090A1/en unknown
- 2004-05-20 ZA ZA200403907A patent/ZA200403907B/en unknown
- 2004-05-20 CO CO04046633A patent/CO5580794A2/en not_active Application Discontinuation
- 2004-05-26 NO NO20042182A patent/NO20042182L/en not_active Application Discontinuation
-
2006
- 2006-07-14 JP JP2006193577A patent/JP2006321808A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL374354A1 (en) | 2005-10-17 |
| CO5580794A2 (en) | 2005-11-30 |
| AP2004003050A0 (en) | 2004-06-30 |
| JP2006321808A (en) | 2006-11-30 |
| CA2467731A1 (en) | 2003-05-30 |
| EA200400565A1 (en) | 2005-06-30 |
| ECSP045114A (en) | 2004-07-23 |
| AU2002356990A1 (en) | 2003-06-10 |
| MA27544A1 (en) | 2005-10-03 |
| GEP20063860B (en) | 2006-06-26 |
| EA008505B1 (en) | 2007-06-29 |
| OA13063A (en) | 2006-11-10 |
| EP1453859A2 (en) | 2004-09-08 |
| EA200700431A1 (en) | 2008-02-28 |
| BR0214451A (en) | 2006-05-30 |
| WO2003044056A2 (en) | 2003-05-30 |
| HRP20040448A2 (en) | 2006-02-28 |
| MXPA04004809A (en) | 2004-08-11 |
| ZA200403907B (en) | 2007-12-27 |
| IS7268A (en) | 2004-05-17 |
| WO2003044056A3 (en) | 2003-08-21 |
| RS53104A (en) | 2006-10-27 |
| CN1608079A (en) | 2005-04-20 |
| KR20070072924A (en) | 2007-07-06 |
| KR20050044858A (en) | 2005-05-13 |
| TNSN04090A1 (en) | 2006-06-01 |
| HUP0500997A2 (en) | 2007-11-28 |
| NO20042182L (en) | 2004-08-11 |
| JP2005525302A (en) | 2005-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL162031A0 (en) | Chemically-modified human growth hormone conjugates | |
| AU2002342653A8 (en) | Modified growth hormone | |
| AU9175801A (en) | Flexible implant | |
| AU2003304235A1 (en) | Chemically-modified human growth hormone conjugates | |
| GB0100658D0 (en) | Crystallisation - resistant aqueous growth hormone formulations | |
| IL153067A0 (en) | Growth hormone secretagogues | |
| HUP0402496A3 (en) | Growth hormone fusion protein | |
| IL147253A0 (en) | Growth hormone formulations | |
| AU2001272974A1 (en) | Human receptors | |
| GB2411404B (en) | Biologically active peptide conjugates | |
| GB0119665D0 (en) | Conjugates | |
| GB0319495D0 (en) | An implant | |
| HUP0402334A3 (en) | Modified human growth hormone | |
| EP1385556A4 (en) | Gastrin-receptor-avid peptide conjugates | |
| GB0106565D0 (en) | Growth hormone treatment | |
| AU2002343197A8 (en) | Biologically active complex | |
| EP1373299A4 (en) | Connective tissue growth factor-2 | |
| GB0111277D0 (en) | Gentle marker | |
| AU2002364314A8 (en) | Growth hormone agonist peptides and their uses | |
| GB2382347B (en) | Hemoglobin conjugates | |
| GB0408136D0 (en) | A human G protein coupled receptor | |
| GB0127214D0 (en) | Growth hormone variations in humans an their uses | |
| AU145153S (en) | Implant | |
| AU143439S (en) | Curved crop lifter | |
| AU2002233107A1 (en) | Longitudinal implant |